HD1916
Phase 3Small molecule
HD1916 is one of 32 small molecule programs targeting Obesity. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
392 competitors in Obesity
#DrugCompanyPhaseTrials
1HD1916
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 3
Actemra
RochePreclinical
Avapro
SanofiPreclinical
Amidate
PfizerPreclinical
Adenocard
AstellasPreclinical
Colcrys
Alnylam PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Prometrium
FerringPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Obesity1 trial
Semaglutide in Treatment of Obesity
Active, not recruiting·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 3·NCT06604624·462 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HD1916. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details